Vifor Pharma

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, CSL, Probability, Commercial Court (England and Wales), Dialysis, Nephrology, ASX, Patient, ART, Commercial Court, Accounting, Element, LR, Fresenius Medical Care, SIX Swiss Exchange, Commerce, Marketing, Risk, Vifor Pharma

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma AG ("Vifor") announced today that the Commercial Court St.Gallen has cancelled (kraftlos erklrt) all remaining publicly held registered shares of Vifor with a nominal value of CHF0.01 each (each a "Vifor Share").
  • Vifor further announced today that SIX Exchange Regulation AG has determined the last trading day and the delisting date of the Vifor Shares at and from SIX Swiss Exchange as follows:
    As a result of the cancellation of the remaining publicly held Vifor Shares, each holder of cancelled Vifor Shares is entitled to a compensation of USD179.25 in cash per cancelled Vifor Share.
  • The envisaged settlement date for payment of such compensation against delivery of the cancelled Vifor Shares is 28 December 2022.
  • Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

Approval of extension of exemptions from SIX disclosure and publicity obligations

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Federal Act on Banks and Savings Banks, Element, CSL, Risk, Dialysis, DFR, ASX, VI, Financial Market Infrastructure Act, ART, Patient, DAH, Judgement, RLR, LR, Fresenius Medical Care, Probability, III, Marketing, Non bis in idem, Derivative, Accounting, SER, Forward-looking statement, Section, FMIA, Disclosure, Nephrology, Rope, Adhesive, Security (finance), Vifor Pharma, Ziff, Surface-conduction electron-emitter display, Issuer

Art.

Key Points: 
  • Art.
  • Art.
  • Februar 2023 eintritt:
    a. Eintritt eines Minderheitsaktionrs oder mehrerer Minderheitsaktionre in das Verfahren um Kraftloserklrung der Namensaktien des Emittenten nach Art.
  • letter a. to d. occur until 28 February 2023, the Issuer's obligations pursuant to Section I shall revive immediately.

Approval of delisting of Vifor Pharma AG's registered shares

Retrieved on: 
Wednesday, October 12, 2022
Biotechnology, Pharmaceutical, Health, Element, CSL, Risk, Dialysis, ASX, ART, Patient, CHF, Fresenius Medical Care, LR, Probability, Commercial Court (England and Wales), Marketing, Commercial Court, Accounting, SER, Forward-looking statement, SWX, Nephrology, Pharmaceutical industry, Risk management, Vifor Pharma

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's registered shares.
  • On August 18, Vifor applied to SIX Exchange Regulation AG (SER) for the delisting of the totality of its registered shares.
  • With its decision of October 11, 2022, SER approved the delisting of all registered shares of Vifor with a par value of CHF 0.01 each.
  • SER will determine the last trading day and the delisting date in consultation with Vifor after the issuance of the legally binding decision by the Commercial Court St. Gallen regarding the cancellation of the remaining publicly held registered shares of Vifor.

RSN's 29th Annual Virtual Patient Education & Lifestyle Meeting

Retrieved on: 
Thursday, October 6, 2022
Emotion, AstraZeneca, Hartwell, Chronic kidney disease, Therapy, Dialysis, Amgen, Body image, Vifor Pharma, Hope, Education, Patient, Kidney, Transplant, Knowledge, RSN, MD, Kidney disease, Pet, CKD, FASN, Renal Support Network, DVM, Pharmaceutical industry, Medical device

GLENDALE, Calif., October 06, 2022 /PRNewswire-PRWeb/ -- Renal Support Network (RSN) will host its 29th Annual Patient Education and Lifestyle Meeting October 18–22, 2022. For almost three decades, RSN has hosted this educational event for people living with kidney disease as well as those who help care for them who want to learn more about navigating care. After the notable success of the virtual meetings, RSN will continue this five-day virtual event.

Key Points: 
  • GLENDALE, Calif., October 06, 2022 /PRNewswire-PRWeb/ -- Renal Support Network (RSN) will host its 29th Annual Patient Education and Lifestyle Meeting October 1822, 2022.
  • After the notable success of the virtual meetings, RSN will continue this five-day virtual event.
  • Each day, the focus will be on a specific stage or aspect of chronic kidney disease (CKD).
  • A special day for youth who have kidney disease will feature a youth workshop and a youth patient experience panel.

Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

Retrieved on: 
Wednesday, September 21, 2022
Proteinuria, Gaps, Jay Traver, Vifor Pharma, Pulse, Steroid, ESRD, Nephrology, Vertex, Growth, Empagliflozin, Patient, Physician, AstraZeneca, Genetic testing, ACE, Diagnosis, IgA nephropathy, SGLT2, Focal segmental glomerulosclerosis, Research, Awareness, FSGS, ARB, Immunoglobulin A, Nephrotic syndrome, Pharmaceutical industry, EU

EXTON, PA., Sept. 21, 2022 /PRNewswire/ -- Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of nephrotic syndrome across the world and is considered the most common glomerular cause of end-stage renal disease (ESRD).1 Spherix has been tracking the evolution of the FSGS market since 2018 to keep a pulse on how nephrologists are treating patients and the perceived potential for products as they make their way through development.

Key Points: 
  • Over the past few months, Spherix has released two reports revealing insights from both US-based and EU5-based nephrologists as a part of its Market Dynamix: Focal Segmental Glomerulosclerosis (FSGS) research services.
  • Of note, Spherix experts found that while most FSGS patients are still confirmed via kidney biopsies, nephrologists are becoming increasingly likely to use genetic testing for diagnosis.
  • In fact, reported use of SGLT2 inhibitors in primary FSGS patients more than doubled year-over-year in both regions captured in these studies, with expectations for continued growth.
  • To gauge pipeline product potential, Spherix assessed awareness, familiarity, desire to have approved, likelihood to prescribe, and estimated patient candidacy for the following assets:

Senior Global Regulatory Affairs Executive, Dr. Daniela Drago, Joins NDA Partners as Expert Consultant

Retrieved on: 
Wednesday, September 7, 2022
Swiss Federal Institute of Technology, University, Pharmaceutical medicine, Swiss, Pharmacokinetics, Ophthalmology, Program, Gene, Cell, ETH, Executive Committee, Biogen, Doctor of Philosophy, Associate, Bausch & Lomb, Medical school, American Society of Gene and Cell Therapy, Society, Bausch, University of Messina, Swiss Federal Institute of Aquatic Science and Technology, ECPM, Biozentrum University of Basel, CMC, School, Drug development, Neurology, Roche, Regulatory science, George Washington University, History, George Washington University School of Medicine & Health Sciences, Biotechnology, Regulatory affairs, University of California, San Francisco, UCSF, Toxicology, MS, RAPS, Vifor Pharma, USP, FRAPS, General manager, Medical device, Pharmaceutical industry, Medicine, Chemistry

WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant. Dr. Drago is a regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles. She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb. She was formerly an Associate Professor at George Washington University's School of Medicine where she redesigned and led the regulatory affairs program. Currently, she is an Adjunct Faculty for the University of California, San Francisco (UCSF), American Course on Drug Development and Regulatory Sciences (ACDRS), and the University of Basel, European Center of Pharmaceutical Medicine (ECPM).

Key Points: 
  • NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • Dr. Drago has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
  • WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago , a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

VFMCRP announces U.S. Court upholds validity of Velphoro® patent

Retrieved on: 
Monday, August 22, 2022
Medical Supplies, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Orange Book, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Fresenius Medical Care, District court, Sucroferric oxyhydroxide, Chronic kidney disease, Teva, Vifor Pharma, Judgement, Blood, Dialysis, CSL, Patent, Multimedia, Nephrology, ANDA, District, Douglas v. U.S. District Court ex rel Talk America, Abbreviated New Drug Application, ASX, Intellectual property, Anders (singer), Marketing, Patient, Generic drug

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRPs favor regarding U.S. patent no.

Key Points: 
  • Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRPs favor regarding U.S. patent no.
  • Currently, Velphoro is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
  • View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
    A further ANDA patent infringement lawsuit against Teva based on patents no.
  • CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro which highlights the innovation and strength of our intellectual property, said Florian Jehle, Chief Executive Officer of VFMCRP.

CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY

Retrieved on: 
Wednesday, August 10, 2022
CSL Limited, Name, Integrity, CSL, Patient, DNA, Perreault, Family, Value (ethics), Biotechnology, Vifor Pharma, Plasma, Health, CSL Behring, Pharmaceutical industry

MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.

Key Points: 
  • MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.
  • "As a purpose-driven organization, CSL has delivered biotechnology excellence for over a century," said Paul Perreault, Chief Executive Officer and Managing Director of CSL.
  • CSL Behring, which delivers therapies for rare and serious diseases, will maintain its current identity, as will CSL Plasma, the company's plasma collection business.
  • For more information on the new CSL brand identity, visit: drivenbyourpromise.csl.com.

CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY

Retrieved on: 
Wednesday, August 10, 2022
CSL Limited, Name, Integrity, CSL, Patient, DNA, Perreault, Family, Value (ethics), Biotechnology, Vifor Pharma, Plasma, Health, CSL Behring, Pharmaceutical industry

MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.

Key Points: 
  • MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Global biotech leader CSL today announced that all business units will be united as one family under the CSL global brand.
  • "As a purpose-driven organization, CSL has delivered biotechnology excellence for over a century," said Paul Perreault, Chief Executive Officer and Managing Director of CSL.
  • CSL Behring, which delivers therapies for rare and serious diseases, will maintain its current identity, as will CSL Plasma, the company's plasma collection business.
  • For more information on the new CSL brand identity, visit: drivenbyourpromise.csl.com.

Cara Therapeutics Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Chronic kidney disease, Dialysis, Canaccord Genuity, Primary biliary cholangitis, Vifor Pharma, GLOBE, Liver, PBC, R, NP, Private Securities Litigation Reform Act, Growth, Investment, Sale, Notalgia paresthetica, Conference call, Security (finance), Research and development, Patient, Instagram, Therapy, COVID-19, Company, Twitter, Itch, Program, COGS, CKD, Safety, Particle-size distribution, G&A, Form 10-Q, Atopic dermatitis, Research, AD, KICK, Nasdaq, KIND, Royal commission, LinkedIn, Conference, European Commission, Food, Administration, Adult, Organization, Medical device, Pharmaceutical industry, Video game, Online gambling, Animal, Cryptocurrency, Income

STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2022.

Key Points: 
  • ET
    STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2022.
  • During the second quarter of 2022, we made great strides toward establishing Cara Therapeutics as the leader in the treatment of chronic pruritus, said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • KORSUVA injection generated net sales of $16.8 million in the second quarter of 2022, translating into $8 million in profit-sharing revenue for Cara.
  • The Company expects the commercial launches of Kapruvia to commence in certain European markets in the second half of 2022.